MedWatch

Janssen sees USD 12bn sales potential in Genmab-developed drugs

Three potential candidates from Genmab have a USD 4bn top sales potential each, says Head of the Global Oncology Therapeutic Area at Janssen Peter Lebowitz.

Photo: BRENDAN MCDERMID/REUTERS / X90143

Genmab is already bringing in most of its top line revenue from partner Johnson & Johnson's sales of Darzalex, which is a Genmab-developed drug, but revenue streams from Johnson & Johnson's pharmaceutical arm could be considerably increased in the future, reports Danish business daily Børsen.

In a presentation, Peter Lebowitz, head of the Global Oncology Therapeutic Area at Janssen, says that six more portfolio candidates could see approvals or submissions for approvals before the end of 2023 – three of which are potential candidates developed by Genmab.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs